1.Reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
2. Reduce the risk of first myocardial infarction or stroke in patients with coronary artery disease at high risk for these events.
3.Reduce the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack.

Antiplatelet Agent; P2Y12 Antagonist
Reversibly and noncompetitively binds the adenosine diphosphate (ADP) P2Y12 receptor on the platelet surface which prevents ADP-mediated activation of the GPIIb/IIIa receptor complex thereby reducing platelet aggregation.

1.Absorption: Rapid
2.Distribution: 88 L
3.Protein binding: >99% (parent drug and active metabolite)
4.Metabolism: Hepatic via CYP3A4/5 to active metabolite (AR-C124910XX)
5.Half-life elimination: Parent drug: ~7 hours; active metabolite: ~9 hours
6.Excretion: Feces (58%); urine (26%)

Hypersensitivity (eg, angioedema) to ticagrelor or any component of the formulation; active pathological bleeding (eg, peptic ulcer, intracranial hemorrhage); history of intracranial hemorrhage

Excretion into breast milk is unknown; use is not recommended.

1.Respiratory: Dyspnea
2.Cardiovascular: ECG abnormality
3.Gastrointestinal: Nausea (4%)
4.Hematologic & oncologic: Hemorrhage
5.Nervous system: Dizziness (5%)
6.Renal: Increased serum creatinine (4% to 7%; transient)

Acute coronary syndrome:Ticagrelor loading dose 180 mg orally once plus aspirin (usually 325 mg), followed by a maintenance dose of ticagrelor 90 mg twice daily with aspirin 75 to 100 mg once daily.
Coronary artery disease (stable) and high risk for ischemic cardiovascular events, primary prevention:60 mg twice daily in combination with aspirin.
Minor ischemic stroke:180 mg once in combination with aspirin, followed by 90 mg twice daily in combination with aspirin for 21 to 30 days.

Severe impairment: Avoid use